HUS Women's hospital, Helsinki Unversity Hospital
Helsinki, 00029, Finland
NCT Number: NCT03765684
In Helsinki Birth Cohort 2018-2022 a large, longitudinal and well-phenotyped birth cohort of infants and their parents will be established. Mothers, fathers/spouses and their children in Helsinki and Uusimaa Hospital District are recruited in the study and newborn composition of the children born in Helsinki Women's Hospital will be measured. Data on maternal and paternal diet quality, physical activity and depression during and after pregnancy will be collected and data from the hospital and national registers will be collected. Health of offspring and parents will be followed during their later life.
This study is active but is not currently recruiting participants.
All sexes
Observational
Helsinki, 00029, Finland
Helsinki Birth Cohort 2018-2022 (HeBiCo) study is designed to find evidence between various intrauterine exposures and offspring adiposity and later health. It will be examined how different maternal (e.g. chronic diseases, ethnicity, BMI), and obstetric factors (e.g. gestational weight gain, diagnoses during pregnancy) as well as parental lifestyle and psychological aspects (e.g. diet quality, physical activity, depression and anxiety) are associated with newborn body composition and later health (e.g. obesity and neurocognitive health).
In the first phase of the study the participants are recruited on postnatal ward after delivery. The umbilical cord blood sample will be collected of all the neonates. After a consent the participants fill in the digital background, food frequency, depression and physical activity questionnaires. If the parents do not give their consent, the umbilical cord blood sample will be destroyed. Body composition of offspring will be assessed within 72 hours after birth. Registry data will be collected.
The second phase of the HeBiCo study is based on the HUS WomensHub treatment path and/or Apotti platform. The second phase of the HeBiCo constitutes of the mother-child pairs (and fathers/spouses) whose pregnancy can be followed from the early pregnancy to the end of the pregnancy through treatment path. Body composition of offspring born in Helsinki Women's Hospital will be assessed within 72 hours after birth.
The future studies will include 1) the intervention studies with digital service concept through WomensHub platform, and 2) the follow-up studies of offspring and parents in later life (to establish e.g. growth trajectories and later metabolic health of offspring).
The first phase of the HeBiCo study was registered 3/2018.
The second phase will be registered now.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Mothers, fathers/spouses and offspring in Helsinki and Uusimaa Hospital District.
Exclusion criteria
Inability to communicate in Finnish language
Time frame: Within 72 hours of birth
Measured with PEA POD Cosmed® Infant Body Composition Assessment system
Time frame: Within 2 hours of birth
Birth weight in kilograms
Time frame: Within 2 hours of birth
Birth height in meters
Time frame: 3 months, 1 year and 2 years of age
Ages and Stages Questionnaire-3
Time frame: 3 months, 1 year and 2 years of age
Infant Toddler Social Emotional Assessment
Helsinki University Central Hospital
Other
Effects of Various Parental and Gestational Factors on Offspring Body Composition and Health in Later Life in Helsinki Birth Cohort 2018-2022
Acronym: HeBiCo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07291258
Cardiovascular Abnormalities, Cardiovascular Diseases
Groningen, Provincie Groningen, Netherlands
View Trial DetailsNCT06958640
Cancer, Cardiovascular Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT03650829
ART, Genetics
Guangzhou, Guangdong, China
View Trial DetailsNCT03742011
46, XX Disorders of Sex Development, Adrenogenital Syndrome
Guangzhou, Guangdong, China
View Trial Details